|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sadlecki P, Bodnar M, Grabiec M, Marszalek
A, Walentowicz P, Sokup A, Zegarska J and Walentowicz-Sadlecka M:
The role of Hypoxia-inducible factor 1α, glucose transporter-1
(GLUT-1) and carbon anhydrase IX in endometrial cancer patients.
Biomed Res Int. 2014:6168502014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Daniilidou K, Frangou-Plemenou M,
Grammatikakis J, Grigoriou O, Vitoratos N and Kondi-Pafiti A:
Prognostic significance and diagnostic value of PTEN and p53
expression in endometrial carcinoma. A retrospective
clinicopathological and immunohistochemical study. J BUON.
18:195–201. 2013.PubMed/NCBI
|
|
4
|
Talhouk A and McAlpine JN: New
classification of endometrial cancers: The development and
potential applications of genomic-based classification in research
and clinical care. Gynecol Oncol Res Pract. 3:142016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Taoussi N, Alghamdi A, Futyma K and
Rechberger T: Biological markers with potential clinical value in
endometrial cancer-review of the literature. Ginekol Pol.
88:331–336. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mancebo G, Sole-Sedeno JM, Pino O,
Miralpeix E, Mojal S, Garrigos L, Lloveras B, Navarro P, Gibert J,
Lorenzo M, et al: Prognostic impact of CD133 expression in
endometrial cancer patients. Sci Rep. 7:76872017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang HM, Fan TT, Li W and Li XX:
Expressions and significances of TTF-1 and PTEN in early
endometrial cancer. Eur Rev Med Pharmacol. 21 (3 Suppl):S20–S26.
2017.
|
|
8
|
Hashmi AA, Hussain ZF, Qadri A, Irfan M,
Ramzan S, Faridi N, Khan A and Edhi MM: Androgen receptor
expression in endometrial carcinoma and its correlation with
clinicopathologic features. BMC Res Notes. 11:2892018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bakkum-Gamez JN, Gonzalez-Bosquet J, Laack
NN, Mariani A and Dowdy SC: Current issues in the management of
endometrial cancer. Mayo Clin Proc. 83:97–112. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rudin CM and Thompson CB: Apoptosis and
disease: Regulation and clinical relevance of programmed cell
death. Annu Rev Med. 48:267–281. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
LaCasse EC, Baird S, Korneluk RG and
MacKenzie AE: The inhibitors of apoptosis (IAPs) and their emerging
role in cancer. Oncology. 17:3247–3259. 1998.
|
|
13
|
Tamm I, Wang Y, Sausville E, Scudiero DA,
Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin
inhibits caspase activity and apoptosis induced by Fas (CD95), Bax,
caspases, and anticancer drugs. Cancer Res. 58:5315–5320.
1998.PubMed/NCBI
|
|
14
|
Altieri DC: Survivin, cancer networks and
path-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cohen C, Lohmann CM, Cotsonis G, Lawson D
and Santoianni R: Survivin expression in ovarian carcinoma:
Correlation with apoptotic markers and prognosis. Mod Pathol.
16:574–583. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Takai N, Miyazaki T, Nishida M, Nasu K and
Miyakawa I: Survivin expression correlates with clinical stage,
histological grade, invasive behavior and survival rate in
endometrial carcinoma. Cancer Lett. 184:105–116. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tran J, Master Z, Yu JL, Rak J, Dumont DJ
and Kerbel RS: A role for survivin in chemoresistance of
endothelial cells mediated by VEGF. Proc Natl Acad Sci USA.
99:4349–4354. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Altieri DC: Survivin, versatile modulation
of cell division and apoptosis in cancer. Oncogene. 22:8581–8589.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Altieri DC: Survivin and apoptosis
control. Adv Cancer Res. 88:31–52. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mita AC, Mita MM, Nawrocki ST and Giles
FJ: Survivin: Key regular of mitosis and apoptosis and novel target
for cancer therapeutics. Clin Cancer Res. 14:5000–5005. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li F, Ambrosini G, Chu EY, Plescia J,
Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and
mitotic spindle checkpoing by survivin. Nature. 396:580–584. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mahotka C, Wenzel M, Springer E, Gabbert
HE and Gerharz CD: Survivin-deltaEx3 and survivin-2B: Two novel
splice variants of the apoptosis inhibitor survivin with different
antiapoptotic properties. Cancer Res. 59:6097–6102. 1999.PubMed/NCBI
|
|
23
|
Zhang M, Yang J and Li F: Transcriptional
and post-transcriptional controls of survivin in cancer cells:
Novel approaches for cancer treatment. J Exp Clin Cancer Res.
25:391–402. 2006.PubMed/NCBI
|
|
24
|
Dohi T, Beltrami E, Wall NR, Plescia J and
Alteiri DC: Mitochondrial survivin inhibits apoptosis and promotes
tumorigenesis. J Clin Invest. 114:1117–1127. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sui L, Dong Y, Ohno M, Watanabe Y,
Sugimoto K and Tokuda M: Survivin expression and its correlation
with cell proliferation and prognosis in epithelial ovarian tumors.
Int J Oncol. 21:315–120. 2002.PubMed/NCBI
|
|
26
|
Guha M, Plescia J, Leav I, Li J, Languino
LR and Altieri DC: Endogenous tumor suppression mediated by PTEN
involves survivin gene silencing. Cancer Res. 69:4954–4958. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim S, Kang J, Qiao J, Thomas RP, Evers BM
and Chung DH: Phosphatidylinositol 3-kinase inhibition
down-regulates survivin and facilitates TRAIL-mediated apoptosis in
neuroblastomas. J Padiatr Surg. 39:516–521. 2004. View Article : Google Scholar
|
|
28
|
Sui L, Dong, Watanabe Y, Yamaguchi F,
Sugimoto K and Tokuda M: Alteration and clinical relevance of PTEN
expression and its correlation with survivin expression in
epithelial ovarian tumors. Oncol Rep. 15:773–778. 2006.PubMed/NCBI
|
|
29
|
Grossman D, Kim PJ, Blanc-Brude OP, Brash
DE, Tognin S, Marchisio PC and Altieri DC: Transgenic expression of
survivin in keratinocytes counteracts UVB-induced apoptosis and
cooperates with loss of p53. J Clin Invest. 108:991–999. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hoffman WH, Biade S, Zilfou JT, Chen J and
Murphy M: Trascriptional repression of the anti-apoptotic survivin
gene by wild type p53. J Biol Chem. 277:3247–3257. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mirza A, McGuirk M, Hockenberry TN, Wu Q,
Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, et al:
Human survivin is negatively regulated by wild-type p53 and
participates in p53-dependent apoptotic pathway. Oncogene.
21:2613–2622. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kannangai R, Wang J, Liu QZ, Sahin F and
Torbenson M: Survivin overexpression in hepatocellular carcinoma is
associated with p53 dysregulation. Int J Gastrointest Cancer.
35:53–60. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Felisiak-Golabek A, Rembiszewska A,
Rzepecka IK Szafron L, Madry R, Murawska M, Napiorkowski T,
Sobiczewski P, Osuch B and Kupryjanczyk J; PolishOvarian Cancer
Study Group (POCSG), : Nuclear survivin expression is a positive
prognostic factor in taxane-platinum-treated ovarian cancer
patients. J Ovarian Res. 4:202011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gąsowska-Bodnar A, Bodnar L, Dąbek A,
Cichowicz M, Jerzak M, Cierniak S, Kozłowski W and Baranowski W:
Survivin expression as a prognostic factor in patients with
epithelial ovarian cancer or primary peritoneal cancer treated with
neoadjuvant chemotherapy. Int J Gynecol Cancer. 24:687–696. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gonzalez S, Aubert S, Kerdraon O, Haddad
O, Fantoni JC, Bisere J and Lorey X: Prognostic value of combined
p53 and survivin in pT1G3 urothelial carcinoma of the bladder. Am J
Clin Pathol. 129:232–237. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pallares J, Martínez-Guitarte JL, Dolcet
X, Llobet D, Rue M, Palacios J, Prat J and Matias-Guiu X: Survivin
expression in endometrial carcinoma: A tissue microarray study with
correlation with PTEN and STAT-3. Int J Gynecol Pathol. 24:247–253.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Erkanli S, Kayaselcuk F, Kuscu E, Bagis T,
Bolat F, Haberal A and Demirhan B: Expression of survivin, PTEN and
p27 in normal, hyperplastic, and carcinomatous endometrium. Int J
Gynecol Cancer. 16:1412–1418. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lambropoulou M, Papadopoulos N, Tripsianis
G, Alexiadis G, Pagonopoulou O, Kiziridou A, Liberis V, Kakolyris S
and Chatzaki E: Co-expression of survivin, c-erbB2, and
cyclooxygenase-2 (COX-2): Prognostic value and survival of
endometrial cancer patients. J Cancer Res Clin Oncol. 136:427–435.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yilmaz E, Koyuncuoglu M, Görken IB, Okyay
E, Saatli B, Ulukus EC and Saygili U: Expression of matrix
metalloproteinase-2 and survivin in endometrioid and
nonendometrioid endometrial cancers and clinicopathologic
significance. J Gynecol Oncol. 22:89–96. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Brunner A, Riss P, Heinze G and Brustmann
H: pHH3 and survivin are co-expressed in high-risk endometrial
cancer and are prognostic relevant. Br J Cancer. 107:84–90. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Erkanli S, Bolat F, Kayaselcuk F, Demirhan
B and Kuscu E: COX-2 and survivin are overexpressed and positively
correlated in endometrial carcinoma. Gynecol Oncol. 104:320–325.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Aksoy RT, Turan AT, Boran N, Tokmak A,
Isikdogan BZ, Tulunay HG and Dogan M: Lack of relation of survivin
gene expression with survival and surgical prognostic factors in
endometrial carcinoma patients. Asian Pac J Cancer Prev.
15:6905–6910. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Stavropoulos A, Varras M, Vasilakaki T,
Varra VK, Tsavari A, Varra FN, Nonni A, Kavantzas N and Lazaris AC:
Expression of p53 and PTEN in human primary endometrial carcinomas:
Clinicopathological and immunohistochemical analysis and study of
their concomitant expression. Oncol Lett. 17:4575–4589.
2019.PubMed/NCBI
|
|
44
|
Lehner R, Enomoto T, McGregor JA, Shroyer
L, Haugen BR, Pugazhenthi U and Shroyer KR: Correlation of survivin
mRNA detection with histologic diagnosis in normal endometrium and
endometrial carcinoma. Acta Obstet Gynecol Scand. 81:162–167. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chuwa AH, Sone K, Oda K, Ikeda Y, Fukuda
T, Wada-Hiraike O, Inaba K, Makii C, Takeuchi M, Oki S, et al:
Significance of survivin as a prognostic factor and a therapeutic
target in endometrial cancer. Gynecol Oncol. 141:564–569. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Saitoh Y, Yaginuma Y and Ishikawa M:
Analysis of Bcl-2, Bax and survivin genes in uterine cancer. Int J
Oncol. 15:137–141. 1999.PubMed/NCBI
|
|
47
|
Konno R, Yamakawa H, Utsunomiya H, Ito K,
Sato S and Yajima A: Expression of survivin and Bcl-2 in normal
human endometrium. Mol Hum Reprod. 6:529–534. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ai Z, Yin L, Zhou X, Zhu Y, Zhu D, Yu Y
and Feng Y: Inhibition of survivin reduces cell proliferation and
induces apoptosis in human endometrial cancer. Cancer. 107:746–756.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Catasus L, Gallardo A, Cuatrecasas M and
Prat J: Concomitant PI3K-AKT and p53 alterations in endometrial
carcinomas are associated with poor prognosis. Mod Pathol.
22:522–529. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Nout RA, Bosse T, Creutzberg CL,
Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik
EM, van Eijk R, Ter Haar NT and Smit VT: Improved risk assessment
of endometrial cancer by combined analysis of MSI, PI3K-AKT,
Wnt/β-caterin and P53 pathway activation. Gynecol Oncol.
126:466–473. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Uegaki K, Kanamori Y, Kigawa J, Kawaguchi
W, Kaneko R, Naniwa J, Takahashi M, Shimada M, Oishi T, Itamochi H
and Terakawa N: PTEN-positive and phosphorylated-Akt-negative
expression is a predictor of survival for patients with advanced
endometrial carcinoma. Oncol Rep. 14:389–392. 2005.PubMed/NCBI
|
|
52
|
Deveraux QL and Reed JC: IAP family
proteins-suppressors of apoptosis. Genes Dev. 13:239–252. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sanhueza C, Wehinger S, Castillo Bennett
J, Valenzuela M, Owen GI and Quest AF: The twisted survivin
connection to angiogenesis. Mol Cancer. 14:1982015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yan YL and Li XM: The IAP family:
Endogenous caspase inhibitors with multiple biological activities.
Cell Res. 10:169–177. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Mehrotra S, Languino LR, Raskett CM,
Mercurio AM, Dohi T and Altieri DC: IAP regulation of metastasis.
Cancer Cell. 17:53–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Cai X, Ma S, Gu M, Zu C, Qu W and Zheng X:
Survivin regulates the expression of VEGF-C in lymphatic metastasis
of breast cancer. Diagn Pathol. 7:522012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhang J, Zhu Z, Sun Z, Sun X, Wang Z and
Xu H: Survivin gene expression increases gastric cancer cell
hymphatic metastasis by upregulating vascular endothelial growth
factor-C expression levels. Mol Med Red. 9:600–606. 2014.
View Article : Google Scholar
|
|
58
|
Selemtjev S, Savin S, Paunovic I, Tatic S
and Cvejic D: Concomitant high expression of survivin and vascular
endothelial growth factor-C is strong associated with metastatic
status of lymph nodes in papillary thyroid carcinoma. J Cancer Res
Ther. 14 (Suppl):S114–S119. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Nakano J, Huang CL, Liu D, Ueno M,
Sumitomo S and Yokomise H: Survivin gene expression is negatively
regulated by the p53 tumor suppressor gene in non-small cell lung
cancer. Int J Oncol. 27:1215–1221. 2005.PubMed/NCBI
|
|
60
|
Lyu H, Huang J, He Z and Liu B: Epigenetic
mechanist of survivin dysregulation in human cancer. Sci China Life
Sci. 61:808–814. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Chen X, Duan N, Zhang C and Zhang W:
Survivin and tumorigenesis: Molecular mechanisms and therapeutic
strategies. J Cancer. 7:314–323. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Pei SG, Wang JX, Wang XL, Zhang QJ and
Zhang H: Correlation of survivin, p53 and Ki-67 in laryngeal cancer
Hep-2 cell proliferation and invasion. Asian Pac J Trop Med.
8:636–642. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Estève PO, Chin HG and Pradhan S:
Molecular mechanisms of transactivation and doxorubicin-mediated
repression of survivin gene in cancer cells. J Biol Chem.
282:2615–2625. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Smallwood A, Estève PO, Pradhan S and
Carey M: Functional cooperation between HP1 and DNMT1 mediates gene
silencing. Genes Dev. 21:1169–1178. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Nabilsi NH, Broaddus RR and Loose DS: DNA
methylation inhibits p53-mediated survivin repression. Oncogene.
28:2046–2050. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wang Z, Fukuda S and Pelus LM: Survivin
regulates the p53 tumor suppressor gene family. Oncogene.
23:8146–8153. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Guha M and Altieri DC: Survivin as a
global target of intrinsic tumor suppression networks. Cell Cycle.
8:2708–2710. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Calnan DR and Brunet A: The FoxO code.
Oncogene. 27:2276–2288. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Accili D and Arden KC: FoxOs at the
crossroads of cellular metabolism, differentiation, and
transformation. Cell. 117:421–426. 2004. View Article : Google Scholar : PubMed/NCBI
|
